Clinical Trials

Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus placebo in combination with adjuvant chemotherapy with or without radiotherapy for the treatment of newly diagnosed High-Risk Endometrial Cancer after surgery with curative Intent

A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer

Prospective, Observational Study of Low-risk Criteria for Node Metastasis in Endometrial Cancer 

Trial between Two Follow up Regimens with Different Intensity in Endometrial Cancer Treated Patients

Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

Dactinomycin or Methotrexate in Treating Patients with Low Risk Gestational Trophoblastic Neoplasia

A Phase III randomized, open label study of NiraParib maintenance after Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high grade ovarian cancer patientS in first line therapy

A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery

Randomized phase III trial on NIraparib-dostarlimab vs physiscian’s choice CHEmotherapy in recurrent, platinum resistant ovarian, fallopian tube or primary peritoneal cancer

A Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer(SUNNY)

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial Including LOGOS (Low Grade Ovarian Cancer Sub-study).

Randomized, multicenter, open-label, phase 3 study of mirvetuximab
soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane based Chemotherapy in Advanced Ovarian Cancer

Retarded surgery following neoadjuvant chemotherapy in advanced ovarian cancer

A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-Line Complete Cytoreductive Surgery

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study